Biologic therapy in relapsing polychondritis: navigating between options. (4th May 2022)

• Record Type: Journal Article
• Authors: Padoan, Roberto; Campaniello, Debora; Iorio, Luca; Doria, Andrea; Schiavon, Franco
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 5(2022)
• Page Start: 661
• Page End: 671
• Publication Date: 2022-05-04
• Subjects: Relapsing polychondritis -- biological agents -- biologic therapy -- anti-tnfα -- infliximab -- rituximab -- tocilizumab -- anakinra; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2048647
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Relapsing polychondritis (RP) is a rare systemic inflammatory disease of unknown etiology, primarily affecting cartilaginous tissue and proteoglycan-rich structures. Clinical manifestations vary from mild symptoms to occasional organ or life-threatening complications. Treatment can be challenging and is mostly based on experience or case reports/series. Areas covered: There is growing literature investigating the role of biologics in the management of RP. TNFα antagonists, abatacept, tocilizumab, rituximab, anakinra and tofacitinib have been prescribed in several RP patients, mainly as second-line treatment, after conventional immunosuppressive agents' failure. Expert opinion: Glucocorticoids represent the gold standard treatment of RP. Conventional immunosuppressants should be administered in refractory patients or when a glucocorticoid-sparing effect is needed. Biologic therapy should be used after failure of conventional treatments or in severe manifestations. TNFα inhibitors are the most prescribed biologic agent, with partial or complete response in several cases, but loss of efficacy may occur over time. Infliximab and adalimumab should be preferred among TNFα antagonists. Abatacept and tocilizumab proved to be effective as second-line biologic agents, but infections are reported with the former. Data on anakinra and rituximab are controversial, therefore they are not recommended as first-line biologic drugs. The use of JAK inhibitors is still anecdotal.